Introduction　Pacritinib,　a　selective　Janus　kinase　(JAK)　inhibitor,　is　approved　for　the　treatment　of　myelofibrosis　in　adults　with　severe　thrombocytopenia.　However,　its　safety　profile　in　real-world　populations　remains　unclear.　The　aim　of　study　is　provided　a　comprehensive　profile　of　pacritinib＇s　safety　by　evaluating　the　adverse　events　(AEs)　using　a　real-world　pharmacovigilance　database.Methods　Data　from　the　FDA　Adverse　Event　Reporting　System　(FAERS)　database,　spanning　from　the　first　quarter　of　2022　to　the　second　quarter　of　2024,　served　as　the　basis　for　this　analysis.　To　identify　potential　AE　risk　signals,　several　disproportionality　analysis　methods　were　applied,　including　the　reporting　odds　ratio,　the　proportional　reporting　ratio,　the　multi-item　gamma　Poisson　shrinker,　and　the　Bayesian　confidence　propagation　neural　network.Results　A　total　of　4,304,335　AE　reports　were　collected　from　the　FAERS,　with　1,940　reports　identifying　pacritinib　as　the　primary　suspect　drug.　Significant　disproportionality　was　observed　in　the　following　system　organ　classes:　gastrointestinal　disorders,　investigations,　and　surgical　and　medical　procedures.　Common　preferred　terms　were　identified,　including　diarrhea,　fatigue,　death,　nausea,　platelet　count　decreased,　and　hemoglobin　decreased.　Notably,　26　off-label　AEs　were　also　identified.Discussion　Our　study　would　provide　valuable　insights　for　the　post-marketing　safety　surveillance　and　assessment　of　pacritinib,　and　guide　its　clinical　practice.